Sanity Group is a technology company.
Sanity Group has raised $115.0M across 6 funding rounds.
Sanity Group has raised $115.0M in total across 6 funding rounds.
Sanity Group is a Berlin-based technology-driven health and life-science company specializing in cannabinoid-based pharmaceuticals and consumer health products. It develops innovative cannabinoid medicines and wellness solutions aimed at improving quality of life by leveraging the endocannabinoid system. The company serves patients and consumers across Europe, addressing medical needs with precise, consistent dosing and efficacy in its products. Since its founding in 2018, Sanity Group has demonstrated strong growth, supported by strategic investors and expanding its footprint in the European cannabis market[1][2][3][5].
Founded by Finn Hänsel and Fabian Friede, entrepreneurs with backgrounds in consulting, consumer goods, and tech, Sanity Group emerged from a vision to unlock the health benefits of cannabinoids through science and innovation. Early traction included building a multidisciplinary team of experts in medicine, pharmacy, biology, and law, and establishing a medical advisory board to guide product development and regulatory strategy. The company has also been involved in pioneering pilot projects for regulated cannabis sales, such as retail operations in Switzerland, despite some regulatory challenges in Germany[2][4][7].
Sanity Group rides the growing global trend of medical cannabis legalization and the increasing acceptance of cannabinoids in healthcare and wellness. The timing is favorable due to expanding European regulatory frameworks and rising consumer demand for scientifically validated cannabinoid therapies. Market forces such as increased investment in cannabis biotech, advances in extraction technology, and a shift toward personalized medicine work in Sanity Group’s favor. The company influences the ecosystem by bridging pharmaceutical rigor with consumer health innovation, helping to legitimize and professionalize the European cannabis industry[1][2][7].
Looking ahead, Sanity Group is poised to expand its leadership in European cannabinoid pharmaceuticals and consumer health markets. Trends shaping its journey include ongoing regulatory evolution, increased clinical research validating cannabinoid therapies, and broader societal acceptance of cannabis-based products. The company’s influence may grow as it continues to pioneer pilot projects, scale product offerings, and deepen partnerships. Its dual focus on medical and consumer segments positions it well to capitalize on the convergence of health tech, biotech, and wellness trends, potentially becoming a cornerstone of Europe’s emerging cannabis ecosystem[2][7].
Sanity Group has raised $115.0M in total across 6 funding rounds.
Sanity Group's investors include Casa Verde Capital, HV Capital, Redalpine Venture Partners, Sinai Ventures, TQ Ventures, Vine Ventures LP, Dennis Aogo, Howard Schultz, Justin Mateen, Mario Götze, Black Jays Investments, Neil Parikh.
Sanity Group has raised $115.0M across 6 funding rounds. Most recently, it raised $38.0M Series B in September 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2022 | $38.0M Series B | Casa Verde Capital, HV Capital, Redalpine Venture Partners, Sinai Ventures, TQ Ventures, Vine Ventures LP, Dennis Aogo, Howard Schultz, Justin Mateen, Mario Götze | |
| Nov 1, 2021 | $4.0M Series A | Casa Verde Capital, HV Capital, Redalpine Venture Partners, TQ Ventures, Dennis Aogo, Mario Götze | |
| Jun 1, 2021 | $44.0M Series A | Redalpine Venture Partners | |
| Oct 1, 2020 | $5.0M Venture Round | ||
| Feb 1, 2020 | $22.0M Series A | Black Jays Investments, Casa Verde Capital, HV Capital, Sinai Ventures, TQ Ventures, Vine Ventures LP, Howard Schultz, Justin Mateen, Neil Parikh | |
| May 1, 2019 | $2.0M Seed | HV Capital |